Search research articles
Contact Us
Filters
Showing results (31-40 of 39) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 39 results.
Leukemia
|
February 16, 2021
Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapy
Colin D Godwin, George S Laszlo, Salvatore Fiorenza, et al.
Journal of Hematology & Oncology
|
October 22, 2015
High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group
George S Laszlo, Todd A Alonzo, Chelsea J Gudgeon, et al.
Biorxiv : the Preprint Server for Biology
|
March 3, 2023
Multiplex Base Editing to Protect from CD33-Directed Therapy: Implications for Immune and Gene Therapy
Florence Borot, Olivier Humbert, Gregory A Newby, et al.
Blood Advances
|
February 10, 2025
Protection of CD33-modified hematopoietic stem cell progeny from CD33-directed CAR T cells in rhesus macaques
Nicholas E Petty, Stefan Radtke, Greta Kanestrom, et al.
American Journal of Hematology
|
May 21, 2013
Significance of expression of ITGA5 and its splice variants in acute myeloid leukemia: a report from the Children's Oncology Group
Roland B Walter, George S Laszlo, Todd A Alonzo, et al.
Nature Communications
|
May 27, 2025
Multiplex base editing to protect from CD33 directed drugs for immune and gene therapy
Florence Borot, Olivier Humbert, Jeffrey T Ehmsen, et al.
Blood Neoplasia
|
January 5, 2026
Safety of gemtuzumab ozogamicin with cytarabine, daunorubicin, and midostaurin induction in FLT3-mutated AML
Jayanshu Jain, Kelly Pugh, Shivani Handa, et al.
Cancers
|
March 13, 2024
Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET<sup>®</sup> CC-96191
Margaret C Lunn-Halbert, George S Laszlo, Sarah Erraiss, et al.
Blood
|
June 1, 2026
[211At]Astatine-Based Conditioning with a Humanized CD45 Antibody for Autologous Hematopoietic Stem Cell Gene Therapy
Stefan Radtke, George S Laszlo, Kyle Swing, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 39) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 39 results.
Leukemia
|
February 16, 2021
Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapy
Colin D Godwin, George S Laszlo, Salvatore Fiorenza, et al.
Journal of Hematology & Oncology
|
October 22, 2015
High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group
George S Laszlo, Todd A Alonzo, Chelsea J Gudgeon, et al.
Biorxiv : the Preprint Server for Biology
|
March 3, 2023
Multiplex Base Editing to Protect from CD33-Directed Therapy: Implications for Immune and Gene Therapy
Florence Borot, Olivier Humbert, Gregory A Newby, et al.
Blood Advances
|
February 10, 2025
Protection of CD33-modified hematopoietic stem cell progeny from CD33-directed CAR T cells in rhesus macaques
Nicholas E Petty, Stefan Radtke, Greta Kanestrom, et al.
American Journal of Hematology
|
May 21, 2013
Significance of expression of ITGA5 and its splice variants in acute myeloid leukemia: a report from the Children's Oncology Group
Roland B Walter, George S Laszlo, Todd A Alonzo, et al.
Nature Communications
|
May 27, 2025
Multiplex base editing to protect from CD33 directed drugs for immune and gene therapy
Florence Borot, Olivier Humbert, Jeffrey T Ehmsen, et al.
Blood Neoplasia
|
January 5, 2026
Safety of gemtuzumab ozogamicin with cytarabine, daunorubicin, and midostaurin induction in FLT3-mutated AML
Jayanshu Jain, Kelly Pugh, Shivani Handa, et al.
Cancers
|
March 13, 2024
Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET<sup>®</sup> CC-96191
Margaret C Lunn-Halbert, George S Laszlo, Sarah Erraiss, et al.
Blood
|
June 1, 2026
[211At]Astatine-Based Conditioning with a Humanized CD45 Antibody for Autologous Hematopoietic Stem Cell Gene Therapy
Stefan Radtke, George S Laszlo, Kyle Swing, et al.
Page
of 4